MYELOPROLIFERATIVE NEOPLASMS
Clinical trials for MYELOPROLIFERATIVE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASMS trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to control rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug (INCA033989) given alone or with another drug (ruxolitinib) for people with certain blood cancers (myeloproliferative neoplasms). The main goals are to check safety and find the best dose. About 290 adults with these cancers will take part.
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New drug combo aims to control rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug, INCA033989, given alone or with another drug (ruxolitinib) in 225 adults with myeloproliferative neoplasms, a group of blood cancers. The main goal is to check safety and find the best dose. Participants must have a specific gene mutation …
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New drug INCB160058 enters early human testing for rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug, INCB160058, in 186 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check the drug's safety and how the body processes it. Participants must be 18 or older and meet specific disease criteria, includi…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
New drug INCA036978 enters early human testing for rare blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug, INCA036978, in about 218 people with certain blood cancers (myeloproliferative neoplasms). The main goal is to check safety and find the best dose, either alone or with standard treatment. Participants must have a life expectancy over 6 mo…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo therapy targets hard-to-treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs, ivosidenib and ruxolitinib, in people with advanced blood cancers (MPNs) that have a specific IDH1 mutation. The study aims to find the safest dose and see how well the combination works. About 18 participants will be enrol…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug trial aims to tame rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug, INCA035784, in 120 adults with myeloproliferative neoplasms (MPNs), a group of blood cancers. The main goal is to check the drug's safety and find the right dose. Participants must have a specific gene mutation and have tried other treatme…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC